Skip to main content
|
  1. Home
  2. Clinical Trials
  3. S2414/INSIGHT

Immunotherapy After Surgery for Early-Stage Non-Small Cell Lung Cancer

Short Title: S2414/INSIGHT


Enrollment Status: Recruiting

NCT #: NCT06498635

Specialty Area: Oncology

Condition Studied: Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: III


Study Information

Summary / Purpose

To find out if durvalumab after surgery improves disease-free survival compared to observation in patients with early-stage NSCLC who have no remaining cancer cells.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with stage II to IIIB Non-Small Cell Lung Cancer (NSCLC)
  • Standard treatment including surgery is complete
  • No cancer cells found after treatment
  • Meets requirements for immunotherapy

What's Involved

Participation in the study will include:
  • Treatment with durvalumab given intravenously (IV) or no further treatment
  • CT scans to monitor response to treatment
  • Blood and tissue samples to monitor your health and treatment effects
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06498635

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up